[1]阚通,秦永文.二尖瓣关闭不全介入治疗进展[J].心血管病学进展,2016,(1):16-19.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.005]
 KAN Tong,QIN Yongwen.Recent Progress in Transcatheter Therapy of Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(1):16-19.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.005]
点击复制

二尖瓣关闭不全介入治疗进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年1期
页码:
16-19
栏目:
综述
出版日期:
2016-02-20

文章信息/Info

Title:
Recent Progress in Transcatheter Therapy of Mitral Regurgitation
作者:
阚通秦永文
第二军医大学附属长海医院心血管内科, 上海 200433
Author(s):
KAN Tong QIN Yongwen
Department of Cardiology, Changhai Hospital,The Second Military Medical University, Shanghai 200433, China
关键词:
二尖瓣关闭不全 二尖瓣 瓣膜修复
Keywords:
Mitral regurgitation Mitral valve Valve replacement
分类号:
R542.5; R815
DOI:
10.16806/j.cnki.issn.1004-3934.2016.01.005
文献标志码:
A
摘要:
重度二尖瓣关闭不全,可显著降低患者的生存时间。二尖瓣关闭不全的治疗包含药物治疗、外科手术治疗和介入治疗。介入治疗提高了不能手术或高危患者的生活质量和临床转归,新型的二尖瓣介入器械也在不断地研发。现对二尖瓣关闭不全的介入治疗进展做一综述。
Abstract:
Severe mitral regurgitation(MR)is associated with decreased survival rates. The treatment of MR includes medication, surgery and transcatheter therapy. Transcatheter therapy improves the quality of life and clinical outcomes in patients with severe MR. New interventional mitral devices continue to be researched and developed. This paper aims to make a comprehensive review about the recent progress in transcatheter therapy of MR.

参考文献/References:

[1] Trichon BH, Felker GM, Shaw LK, et al. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure[J]. Am J Cardiol, 2003,91(5):538-543.
[2] Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation[J]. Circulation, 2005,111(3):295-301.
[3] Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases:a population-based study[J]. Lancet, 2006,368(9540):1005-1011.
[4] Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2014,63(22):2438-2488.
[5] Ling LH, Enriquez-Sarano M, Seward JB, et al. Clinical outcome of mitral regurgitation due to flail leaflet[J]. N Engl J Med, 1996,335(19):1417-1423.
[6] Nemoto S, Hamawaki M, de Freitas G, et al. Differential effects of the angiotensin-converting enzyme inhibitor lisinopril versus the beta-adrenergic receptor blocker atenolol on hemodynamics and left ventricular contractile function in experimental mitral regurgitation[J]. J Am Coll Cardiol, 2002,40(1):149-154.
[7] Ahmed MI, Aban I, Lloyd SG, et al. A randomized controlled phase Ⅱb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation[J]. J Am Coll Cardiol, 2012,60(9):833-838.
[8] Tischler MD, Rowan M, LeWinter MM. Effect of enalapril therapy on left ventricular mass and volumes in asymptomatic chronic, severe mitral regurgitation secondary to mitral valve prolapse[J]. Am J Cardiol,1998,82(2):242-245.
[9] Harris KM, Aeppli DM, Carey CF. Effects of angiotensin-converting enzyme inhibition on mitral regurgitation severity, left ventricular size, and functional capacity[J]. Am Heart J, 2005,150(5):1106.
[10] Rowe JC, Bland EF, Sprague HB, et al. The course of mitral stenosis without surgery: ten- and twenty-year perspectives[J]. Ann Intern Med,1960,52:741-749.
[11] The SOLVD Investigattors.Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions[J]. N Engl J Med,1992,327(10):685-691.
[12] van Bommel RJ, Marsan NA, Delgado V, et al. Cardiac resynchronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high operative risk[J]. Circulation, 2011,124(8):912-919.
[13] Detaint D, Sundt TM, Nkomo VT, et al. Surgical correction of mitral regurgitation in the elderly: outcomes and recent improvements[J]. Circulation,2006,114(4):265-272.
[14] Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease(version 2012)[J]. Eur Heart J,2012,33(19):2451-2496.
[15] Enriquez-Sarano M, Schaff HV, Orszulak TA, et al. Valve repair improves the outcome of surgery for mitral regurgitation. A multivariate analysis[J]. Circulation,1995,91(4):1022-1028.
[16] Gammie JS, O'Brien SM, Griffith BP, et al. Influence of hospital procedural volume on care process and mortality for patients undergoing elective surgery for mitral regurgitation[J]. Circulation,2007,115(7):881-887.
[17] Mehta RH, Eagle KA, Coombs LP, et al. Influence of age on outcomes in patients undergoing mitral valve replacement[J]. Ann Thorac Surg,2002,74(5):1459-1467.
[18] Alfieri O, Maisano F, de Bonis M, et al. The double-orifice technique in mitral valve repair: a simple solution for complex problems[J]. J Thorac Cardiovasc Surg,2001,122(4):674-681.
[19] Maisano F, Caldarola A, Blasio A, et al. Midterm results of edge-to-edge mitral valve repair without annuloplasty[J]. J Thorac Cardiovasc Surg,2003,126(6):1987-1997.
[20] St GFG, Fann JI, Komtebedde J, et al. Endovascular edge-to-edge mitral valve repair: short-term results in a porcine model[J]. Circulation,2003,108(16):1990-1993.
[21] Silvestry FE, Rodriguez LL, Herrmann HC, et al. Echocardiographic guidance and assessment of percutaneous repair for mitral regurgitation with the Evalve MitraClip: lessons learned from EVERESTⅠ[J]. J Am Soc Echocardiogr,2007,20(10):1131-1140.
[22] Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation[J]. N Engl J Med, 2011,364(15):1395-1406.
[23] Glower D, Ailawadi G, Argenziano M, et al. EVEREST Ⅱ randomized clinical trial: predictors of mitral valve replacement in de novo surgery or after the MitraClip procedure[J]. J Thorac Cardiovasc Surg,2012,143(4 Suppl):s60-s63.
[24] Mauri L, Foster E, Glower DD, et al. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation[J]. J Am Coll Cardiol, 2013,62(4):317-328.
[25] Seeburger J, Rinaldi M, Nielsen SL, et al. Off-pump transapical implantation of artificial neo-chordae to correct mitral regurgitation: the TACT Trial(Transapical Artificial Chordae Tendinae)proof of concept[J]. J Am Coll Cardiol,2014,63(9):914-919.
[26] Herrmann HC, Maisano F. Transcatheter therapy of mitral regurgitation[J]. Circulation, 2014,130(19):1712-1722.
[27] Harnek J, Webb JG, Kuck KH, et al. Transcatheter implantation of the MONARC coronary sinus device for mitral regurgitation:1-year results from the EVOLUTION phase I study(Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System for the Treatment of Mitral Regurgitation)[J]. JACC Cardiovasc Interv,2011,4(1):115-122.
[28] Maselli D, Guarracino F, Chiaramonti F, et al. Percutaneous mitral annuloplasty:an anatomic study of human coronary sinus and its relation with mitral valve annulus and coronary arteries[J]. Circulation,2006,114(5):377-380.
[29] Schofer J, Siminiak T, Haude M, et al. Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study[J]. Circulation,2009,120(4):326-333.
[30] Kim JH, Kocaturk O, Ozturk C, et al. Mitral cerclage annuloplasty, a novel transcatheter treatment for secondary mitral valve regurgitation: initial results in swine[J]. J Am Coll Cardiol,2009,54(7):638-651.
[31] Maisano F, Vanermen H, Seeburger J, et al. Direct access transcatheter mitral annuloplasty with a sutureless and adjustable device: preclinical experience[J]. Eur J Cardiothorac Surg, 2012,42(3):524-529.
[32] Mandinov L, Bullesfeld L, Kuck KH, et al. Early insight into Mitralign direct annuloplasty for treatment of functional mitral regurgitation[J]. Interv Cardiol Rev,2011,6:170-172.
[33] Banai S, Verheye S, Cheung A, et al. Transapical mitral implantation of the Tiara bioprosthesis: pre-clinical results[J]. JACC Cardiovasc Interv,2014,7(2):154-162.

相似文献/References:

[1]阚通,秦永文.二尖瓣反流诊治进展[J].心血管病学进展,2015,(6):686.[doi:10.3969/j.issn.1004-3934.2015.06.008]
 KAN Tong,QIN Yongwen.Recent Progress in Diagnosis and Treatment of Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2015,(1):686.[doi:10.3969/j.issn.1004-3934.2015.06.008]

备注/Memo

备注/Memo:
作者简介:阚通(1990—),在读硕士,主要从事心血管病介入治疗研究。Email: 871415868@qq.com
通信作者:秦永文(1952—),主任医师,教授,博士,主要从事心血管病介入治疗研究。Email: chqinyw@163.com
更新日期/Last Update: 2016-02-20